Inhibition of t-cell engaging agent-related adverse effects

TW202635309APending Publication Date: 2026-09-01F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114141864
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-10-30
Filing Date
2025-10-29
Publication Date
2026-09-01

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
Patent Text Reader

Abstract

The present invention relates to the inhibition of adverse effects related to T cell engaging agents, such as cytokine release syndrome. Specifically, the invention relates to the inhibition of such adverse effects using a tyrosine kinase inhibitor and a glucocorticoid.
Need to check novelty before this filing date? Find Prior Art